Dr. Alexander Edward D. Drilon, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 22
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 91
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 268203
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Memorial Solid Tumor Group (234 clinicians)
- Memorial Developmental Chemo Group (48 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 91
- Services billed
- 226
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 101 | 47 |
| Established patient office or other outpatient visit, 30-39 minutes | 94 | 50 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 21 | 12 |
| New patient office or other outpatient visit, 60-74 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tagrisso (osimertinib mesylate) | 34 |
| Alecensa (alectinib hcl) | 30 |
| Ondansetron Hcl Other prescribers in New York, NY | 26 |
| Xalkori (crizotinib) | 24 |
| Pregabalin Other prescribers in New York, NY | 23 |
| Retevmo (selpercatinib) | 21 |
| Lorazepam Other prescribers in New York, NY | 13 |
| Losartan Potassium Other prescribers in New York, NY | 13 |
| Dexamethasone Other prescribers in New York, NY | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $350 in total to this clinician.
| Bayer HealthCare Pharmaceuticals Inc. | $350 |
|---|
| Consulting Fee | $350 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. Apr 3, 2025 | Consulting Fee | $350 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $931,860 in research payments for these studies, mostly to the institutions running them.
- A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
Eli Lilly and Company · Active, not recruiting · NCT04819100 - A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Eli Lilly and Company · Active, not recruiting · NCT03157128 - A Phase 1/2, Openlabel Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors
E.r. Squibb & Sons, L.l.c. - Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer
Regeneron Pharmaceuticals, Inc. · Terminated · NCT04982224 - BAY 2731953, A Phase 2 Basket Study of the Oral TRK Inhibitor larotrectinib in Subjects with NTRK Fusion-Positive Tumors
Bayer HealthCare Pharmaceuticals Inc. - A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
Eli Lilly and Company · Completed · NCT05241834 - A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT04077099
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.